Employees: 4,702
Size Guizhou Xinbang Pharmaceutical (002390.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $771M, the 2667th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥2.92 on 18 Nov 2026.
Performance Over six months the shares fell 7.3%, against -4.7% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 19 in its peer set.
Growth Revenue fell 12.5% over the last twelve months (peer median +7.3%); the operating margin is 4.5% (peer median 10.4%).
Valuation It trades at 0.9× enterprise value to sales against a peer median of 2.6× (2nd cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.9 points below its cost of capital (7.4% WACC).
Next results Next results expected around 20 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥5.02B | CN¥5.61B | CN¥6.02B | CN¥6.45B | CN¥6.33B |
| Revenue growth | — | -7% | -7% | +2% | — |
| Gross profit | CN¥956M | CN¥878M | CN¥915M | CN¥1.11B | CN¥1.08B |
| EBITDA | n/a | CN¥449M | CN¥498M | CN¥654M | CN¥580M |
| Net income | CN¥138M | CN¥120M | CN¥101M | CN¥287M | CN¥224M |
| Free cash flow | CN¥899M | CN¥667M | CN¥514M | CN¥666M | CN¥466M |
| Capital expenditure | CN¥45.0M | CN¥85.4M | CN¥125M | CN¥136M | CN¥159M |
| Total debt | CN¥541M | CN¥681M | CN¥1.06B | CN¥1.08B | CN¥1.66B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002390.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.5% | -3.8% | 7th highest of 19 |
| 6-month return | -7.3% | -4.7% | 9th lowest of 19 |
| Distance from 52-week high | -29.6% | -33.9% | 6th highest of 19 |
| Revenue growth (TTM) | -12.5% | +7.3% | 3rd lowest of 19 |
| Operating margin | 4.5% | 10.4% | 7th lowest of 19 |
| EV / Sales | 0.9× | 2.6× | 2nd cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -3.8% | 6.6% | least demanding of 12 |
| Growth delivered (Del g) | -0.8% | +2.6% | 3rd lowest of 12 |
| Hurdle (Req g minus delivered) | -3.1 pp | -2.0 pp | 6th least demanding of 12 |
| ROIC minus cost of capital | -2.9 pp | +1.2 pp | 4th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | 0.9× | -3.8% | -0.8% |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | 16.7× | n/a | n/a |
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | 2.4× | 0.3% | +0.5% |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | 6.7× | 33.9% | +10.1% |
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | 0.3× | n/a | n/a |
| Ardelyx ARDX | United States | $784M | -50% | +18% | -8% | 1.6× | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $785M | -8% | +2% | 20% | 3.1× | -2.5% | +2.6% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | 2.5× | 13.5% | -0.2% |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | 5.3× | 9.4% | -1.4% |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | 28.6× | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 2.6× | n/a | n/a |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 1.8× | 6.6% | +17.7% |
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $746M | -3% | +4% | 11% | 1.4× | -2.1% | 0.0% |
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 4.1× | 16.3% | -8.7% |
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 2.5× | 1.5% | +22.1% |
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 3.1× | 13.9% | +27.7% |
| Suven Life Sciences SUVEN.NS | India | $803M | -1% | +55% | -4,452% | 789.4× | n/a | n/a |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 2.3× | -2.6% | +20.3% |